Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Basic therapeutic combination therapy in chronic polyarthritis: an overview]

H Menninger1

  • 1Rheuma-Zentrum I. Medizinische Klinik, Bad Abbach.

Zeitschrift Fur Rheumatologie
|May 5, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Differential diagnosis of polyarthritis pain syndrome of the locomotor apparatus].

Schmerz (Berlin, Germany)·2003
Same author

Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a one-year double-blind study in 174 patients.

Rheumatology (Oxford, England)·2002
Same author

Other pain syndromes to be differentiated from fibromyalgia.

Zeitschrift fur Rheumatologie·1999
Same author

Progression in early erosive rheumatoid arthritis: 12 month results from a randomized controlled trial comparing methotrexate and gold sodium thiomalate.

British journal of rheumatology·1998
Same author

A 36 month comparative trial of methotrexate and gold sodium thiomalate in the treatment of early active and erosive rheumatoid arthritis.

British journal of rheumatology·1998
Same author

Decrease of interleukin 6 during the first 12 months is a prognostic marker for clinical outcome during 36 months treatment with disease-modifying anti-rheumatic drugs.

British journal of rheumatology·1998

Combining methotrexate, azathioprine, and chloroquine offers a beneficial triple therapy for rheumatoid arthritis. This approach shows promise for patients with refractory disease when monotherapy is insufficient.

Area of Science:

  • Rheumatology
  • Clinical Pharmacology

Context:

  • Rheumatoid arthritis (RA) management often requires combination therapy for optimal disease control.
  • Monotherapy may be insufficient for controlling RA progression and symptoms.
  • Various drug combinations have been explored, but study validity is sometimes limited.

Purpose:

  • To evaluate the efficacy of a specific triple drug combination for rheumatoid arthritis.
  • To present findings from a study involving patients with refractory RA.

Summary:

  • A triple combination therapy including methotrexate, azathioprine, and chloroquine was administered to 21 patients with refractory rheumatoid arthritis.
  • The study summarized beneficial experiences with this combination regimen.
  • This approach aims to improve disease control beyond what is achievable with monotherapy.

Related Experiment Videos

Impact:

  • Suggests a potentially effective treatment strategy for difficult-to-treat rheumatoid arthritis.
  • Highlights the value of combination drug therapy in rheumatology.
  • Provides data supporting the use of methotrexate, azathioprine, and chloroquine in combination for RA.